Abstract
Insulin-like growth factor-I is the mediator of many of the actions of GH and is a potent metabolic regulator. Recombinant IGF-I (rhIGF-I) is of potential value in the treatment of syndromes associated with either GH or insulin resistance. This study was designed to assess the effects of subcutaneous (s.c.) rhIGF-I on anterior pituitary function.
Original language | English |
---|---|
Pages (from-to) | 801-7 |
Number of pages | 7 |
Journal | Clinical Endocrinology |
Volume | 41 |
Issue number | 6 |
Publication status | Published - 1994 |